Oxadiazole and its salts, their use in treating dementia

• US 5,106,853 A
• Filed: 05/09/1990
• Issued: 04/21/1992
• Est. Priority Date: 05/15/1989
• Status: Expired due to Fees

• Current Assignee: Merck Sharp & Dohme Limited (Merck & Co., Inc.)
• Original Assignee: Merck Sharp & Dohme Limited (Merck & Co., Inc.)
• Inventors: Street, Leslie J., Showell, Graham A.
• Primary Examiner(s): Lee, Mary C.
• Assistant Examiner(s): WHITTENBAUGH, ROBERT
• Application Number:
  US07/520,891
• Time in Patent Office: 713 Days
• Field of Search: 548/143, 548/131, 514/364, 514/299, 546/112
• US Class Current: 514/299
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C07D 487/08 Bridged systems

Abstract

The compound (3R, 4R)-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-1-azabicyclo[2.2.1]heptane and its salts behave as a functionally selective muscarinic agonist and are useful in the treatment of neurological and mental disorders, preferably in a pharmaceutical formulation comprising the active compound in association with a pharmaceutically acceptable carrier. The compound can be prepared by methods analogous to those known in the art via suitable chiral intermediates and cyclopropyl carboxamide oxime.

Claims

1. A compound, (3R,4R)-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-1-azabicyclo[2.2.1]heptane or salt thereof.

2. The compound according to claim 1, wherein said salt is selected from the group consisting of hydrochloride, hydrogen maleate, hydrogen tartrate and tosylate.

4. A method for the treatment of neurological and mental disorders, wherein said method comprises the administration to a patient in need thereof of a pharmacologically effective amount of a compound according to claim 1.

5. The method according to claim 4, wherein the disorder is dementia.

3. A pharmaceutical composition comprising an effective amount of (3R,4R)-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-1-azabicyclo[2.2.1] heptane or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier.